PF 05089771 is primarily used in research and development within the pharmaceutical industry. It is investigated for its potential as a selective Nav1.7 sodium channel blocker, which makes it a candidate for treating pain-related conditions. Its application focuses on targeting chronic pain disorders, such as neuropathic pain, where modulation of sodium channels can provide therapeutic benefits. Studies explore its efficacy in reducing pain signals by inhibiting specific sodium channels involved in pain perception. This compound is also utilized in preclinical studies to better understand the role of Nav1.7 in pain pathways and to develop more effective pain management therapies.